GLP-1

News

The EU has approved Novo Nordisk's pill formulation of weight-loss therapy Wegovy, keeping the company a step ahead of arch rival Eli Lilly.

News

A $100m trial has been launched to see if lifestyle changes coupled with GLP-1 agonists or similar incretins can reduce the risk of dementia.

News

Fresh from a record-breaking IPO, Kailera revealed keenly anticipated trial results for its oral weight-loss drug, to a mixed reaction.

Oncology

News

Novo Nordisk's fast-growing Wegovy pill has been approved in the UK for weight loss, its first European market.

News

AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.